Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

Front Oncol. 2024 Dec 6:14:1532291. doi: 10.3389/fonc.2024.1532291. eCollection 2024.

Authors

Affiliations

¹ Department of Medicine and Surgery, University of Parma, Parma, Italy.
² Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL - Italian Workers' Compensation Authority, Rome, Italy.
³ Paediatric Hematology Oncology Unit, University Hospital of Parma, Parma, Italy.
⁴ Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.942341.].

Keywords: CDK4/6 inhibition; abemaciclib; hepatocarcinoma (HCC); lenvatinib; senescence.

Copyright © 2024 Digiacomo, Fumarola, La Monica, Bonelli, Cavazzoni, Galetti, Terenziani, Eltayeb, Volta, Zoppi, Bertolini, Missale, Alfieri and Petronini.

Publication types

Published Erratum